系统性红斑狼疮用药模式:多中心队列研究
该研究基于亚太狼疮协作组2013-2018年前瞻性队列数据,分析2860例SLE患者共19804次访视的用药模式。三联治疗最常见(31.4%访视),单药治疗占21%,生物制剂仅3%。糖皮质激素持续率高而免疫抑制剂持续率低,高疾病活动度患者免疫抑制剂停药更早。
要点
- 三联治疗为最常见用药模式,占31.4%访视,单药治疗占21%。
- 抗疟药持续率最高,免疫抑制剂持续率最低,生物制剂使用仅3%。
- 时间调整平均SLEDAI-2K≥10者糖皮质激素停药更少、免疫抑制剂停药更多。
核心结论
- 多数SLE患者接受联合治疗,糖皮质激素持续率高而免疫抑制剂持续率低,高疾病活动度患者免疫抑制剂持续率更低,提示现有治疗存在未满足需求。
研究设计与样本
- 基于亚太狼疮协作组前瞻性队列2013-2018年数据,纳入2860例患者共19804次访视,收集SLEDAI-2K和用药详情,采用Cox回归分析按疾病活动度分层分析停药时间。
主要发现
- 共观察到8类用药模式:未治疗、单用糖皮质激素/抗疟药/免疫抑制剂、糖皮质激素联合抗疟药、糖皮质激素联合免疫抑制剂、抗疟药联合免疫抑制剂、三联治疗。
- 三联治疗占31.4%访视,单药治疗占21%访视,生物制剂仅占3%。
- 停药时间分析显示药物持续率差异大,抗疟药持续率最高,免疫抑制剂最低。
- 时间调整平均SLEDAI-2K≥10的患者糖皮质激素停药更少,免疫抑制剂停药更多。
临床怎么用
- 临床中应关注SLE患者联合用药模式的普遍性,尤其三联治疗的高使用频率。
- 对高疾病活动度患者,需注意免疫抑制剂持续率低可能反映疗效有限,应评估治疗方案的合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evidence for the utility of medications in settings lacking randomized trial data can come from studies of treatment persistence. The present study was undertaken to examine patterns of medication use in systemic lupus erythematosus (SLE) using data from a large multicenter longitudinal cohort. METHODS: Prospectively collected data from the Asia Pacific Lupus Collaboration cohort including disease activity (SLE Disease Activity Index 2000 [SLEDAI-2K]) and medication details, captured at every visit from 2013-2018, were used. Medications were categorized as glucocorticoids (GCs), antimalarials (AM), and immunosuppressants (IS). Cox regression analyses were performed to determine the time-to-discontinuation of medications, stratified by SLE disease activity. RESULTS: Data from 19,804 visits of 2,860 patients were analyzed. Eight medication categories were observed: no treatment; GC, AM, or IS only; GC plus AM; GC plus IS; AM plus IS; and GC plus AM plus IS (triple therapy). Triple therapy was the most frequent pattern (31.4% of visits); single agents were used in 21% of visits, and biologics in only 3%. Time-to-discontinuation analysis indicated that medication persistence varied widely, with the highest treatment persistence for AM and lowest for IS. Patients with a time-adjusted mean SLEDAI-2K score of ≥10 had lower discontinuation of GCs and higher discontinuation of IS. CONCLUSION: Most patients received combination treatment. GC persistence was high, while IS persistence was low. Patients with high disease activity received more medication combinations but had reduced IS persistence, consistent with limited utility. These data confirm unmet need for improved SLE treatments.
引用
- Kandane-Rathnayake R, Louthrenoo W, Luo SF, et al. Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care Res (Hoboken). 2022. PMID: 34197023. doi:10.1002/acr.24740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。